Recently, ZUMA 5 (NCT03105336) assessed the efficacy of axicabtagene ciloleucel, an autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy in relapsed or refractory indolent non‐Hodgkin lymphoma including 24 (16%) MZL.41 Here, CD19 is linked to marginal zone lymphoma.